Russell A Barkley1, Daniel Cox. 1. SUNY Upstate Medical School, Syracuse, NY, USA. russellbarkley@earthlink.net
Abstract
INTRODUCTION: Attention-Deficit/Hyperactivity Disorder (ADHD) may interfere with driving competence, predisposing those with the disorder to impaired driving performance and greater risk for adverse driving outcomes. Effective treatment may minimize the risk in those with ADHD. METHOD: We reviewed the scientific literature on driving risks and impairments associated with ADHD and the effects of stimulants on driving performance. Several lines of evidence were considered, including longitudinal studies and community-derived sample studies. The present review is based on a weekly review (by the first author) of all journals in the behavioral and social sciences indexed in the publication Current Contents spanning the past 15 years, as well as a search of the reference section of all studies found that pertained to driving risks associated with ADHD or to the treatment of ADHD as it relates to driving difficulties. RESULTS: The review of the scientific literature demonstrated well-documented driving risks and impairments associated with ADHD and the positive effects of stimulant medications on driving performance. CONCLUSIONS: Clinicians should educate patients/caregivers about the increased risk of adverse outcomes among untreated individuals with ADHD and the role of medication in potentially improving driving performance. IMPACT ON INDUSTRY: Owing to the significantly higher risk of adverse driving outcomes, the use of stimulant medications to treat people with ADHD who drive may reduce such safety risks.
INTRODUCTION:Attention-Deficit/Hyperactivity Disorder (ADHD) may interfere with driving competence, predisposing those with the disorder to impaired driving performance and greater risk for adverse driving outcomes. Effective treatment may minimize the risk in those with ADHD. METHOD: We reviewed the scientific literature on driving risks and impairments associated with ADHD and the effects of stimulants on driving performance. Several lines of evidence were considered, including longitudinal studies and community-derived sample studies. The present review is based on a weekly review (by the first author) of all journals in the behavioral and social sciences indexed in the publication Current Contents spanning the past 15 years, as well as a search of the reference section of all studies found that pertained to driving risks associated with ADHD or to the treatment of ADHD as it relates to driving difficulties. RESULTS: The review of the scientific literature demonstrated well-documented driving risks and impairments associated with ADHD and the positive effects of stimulant medications on driving performance. CONCLUSIONS: Clinicians should educate patients/caregivers about the increased risk of adverse outcomes among untreated individuals with ADHD and the role of medication in potentially improving driving performance. IMPACT ON INDUSTRY: Owing to the significantly higher risk of adverse driving outcomes, the use of stimulant medications to treat people with ADHD who drive may reduce such safety risks.
Authors: Andrea Chronis-Tuscano; Brooke S G Molina; William E Pelham; Brooks Applegate; Allison Dahlke; Meghan Overmyer; Benjamin B Lahey Journal: Arch Gen Psychiatry Date: 2010-10
Authors: Kristina A Neely; Amanda P Chennavasin; Arie Yoder; Genevieve K R Williams; Eric Loken; Cynthia L Huang-Pollock Journal: Exp Brain Res Date: 2016-07-09 Impact factor: 1.972
Authors: Despina Stavrinos; Annie A Garner; Crystal A Franklin; Haley D Johnson; Sharon C Welburn; Russell Griffin; Andrea T Underhill; Philip R Fine Journal: J Pediatr Nurs Date: 2015-06-03 Impact factor: 2.145
Authors: Paula A Aduen; Michael J Kofler; Dustin E Sarver; Erica L Wells; Elia F Soto; Daniel J Cox Journal: J Psychiatr Res Date: 2018-03-06 Impact factor: 4.791
Authors: E Sobanski; D Sabljic; B Alm; G Skopp; N Kettler; R Mattern; P Strohbeck-Kühner Journal: J Neural Transm (Vienna) Date: 2008-01-16 Impact factor: 3.575
Authors: Sandra J J Kooij; Susanne Bejerot; Andrew Blackwell; Herve Caci; Miquel Casas-Brugué; Pieter J Carpentier; Dan Edvinsson; John Fayyad; Karin Foeken; Michael Fitzgerald; Veronique Gaillac; Ylva Ginsberg; Chantal Henry; Johanna Krause; Michael B Lensing; Iris Manor; Helmut Niederhofer; Carlos Nunes-Filipe; Martin D Ohlmeier; Pierre Oswald; Stefano Pallanti; Artemios Pehlivanidis; Josep A Ramos-Quiroga; Maria Rastam; Doris Ryffel-Rawak; Steven Stes; Philip Asherson Journal: BMC Psychiatry Date: 2010-09-03 Impact factor: 3.630